Time From Colorectal Cancer Surgery to Adjuvant Chemotherapy: Post Hoc Analysis of the SCOT Randomized Clinical Trial

• Published in: JAMA surgery Vol. 159; no. 8; pp. 865 - 871
• Main Authors: Gögenur, Mikail, Rosen, Andreas Weinberger, Iveson, Timothy, Kerr, Rachel S, Saunders, Mark P, Cassidy, Jim, Tabernero, Josep, Haydon, Andrew, Glimelius, Bengt, Harkin, Andrea, Allan, Karen, Pearson, Sarah, Boyd, Kathleen A, Briggs, Andrew H, Waterston, Ashita, Medley, Louise, Ellis, Richard, Dhadda, Amandeep S, Harrison, Mark, Falk, Stephen, Rees, Charlotte, Olesen, Rene K, Propper, David, Bridgewater, John, Azzabi, Ashraf, Cunningham, David, Hickish, Tamas, Gollins, Simon, Wasan, Harpreet S, Kelly, Caroline, Gögenur, Ismail, Holländer, Niels Henrik
• Format: Journal Article
• Language: English
• Published: United States American Medical Association 01.08.2024
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chemotherapy, Adjuvant; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - surgery; Disease-Free Survival; Female; Humans; Male; Middle Aged; Neoplasm Staging; Oxaliplatin - administration & dosage; Oxaliplatin - therapeutic use; Time Factors; Time-to-Treatment
• ISSN: 2168-6254; 2168-6262; 2168-6262
• DOI: 10.1001/jamasurg.2024.1555

IMPORTANCE: The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, with no consensus on the optimal time from surgery to adjuvant chemotherapy. OBJECTIVE: To analyze the association between the timing of adjuvant chemotherapy after surgery for colorectal cancer and disease-free survival. DESIGN, SETTING, AND PARTICIPANTS: This is a post hoc analysis of the phase 3 SCOT randomized clinical trial, from 244 centers in 6 countries, investigating the noninferiority of 3 vs 6 months of adjuvant chemotherapy. Patients with high-risk stage II or stage III nonmetastatic colorectal cancer who underwent curative-intended surgery were randomized to either 3 or 6 months of adjuvant chemotherapy consisting of fluoropyrimidine and oxaliplatin regimens. Those with complete information on the date of surgery, treatment type, and long-term follow-up were investigated for the primary and secondary end points. Data were analyzed from May 2022 to February 2024. INTERVENTION: In the post hoc analysis, patients were grouped according to the start of adjuvant chemotherapy being less than 6 weeks vs greater than 6 weeks after surgery. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival. The secondary end points were adverse events in the total treatment period or the first cycle of adjuvant chemotherapy. RESULTS: A total of 5719 patients (2251 [39.4%] female; mean [SD] age, 63.4 [9.3] years) were included in the primary analysis after data curation; among them, 914 were in the early-start group and 4805 were in the late-start group. Median (IQR) follow-up was 72.0 (47.3-88.1) months, with a median (IQR) of 56 (41-66) days from surgery to chemotherapy. Five-year disease-free survival was 78.0% (95% CI, 75.3%-80.8%) in the early-start group and 73.2% (95% CI, 72.0%-74.5%) in the late-start group. In an adjusted Cox regression analysis, the start of adjuvant chemotherapy greater than 6 weeks after surgery was associated with worse disease-free survival (hazard ratio, 1.24; 95% CI, 1.06-1.46; P = .01). In adjusted logistic regression models, there was no association with adverse events in the total treatment period (odds ratio, 0.82; 95% CI, 0.65-1.04; P = .09) or adverse events in the first cycle of treatment (odds ratio, 0.77; 95% CI, 0.56-1.09; P = .13). CONCLUSIONS AND RELEVANCE: In this international population of patients with high-risk stage II and stage III colorectal cancer, starting adjuvant chemotherapy more than 6 weeks after surgery was associated with worse disease-free survival, with no difference in adverse events between the groups. TRIAL REGISTRATION: isrctn.org Identifier: ISRCTN59757862